Evolving Pathogenic Concepts on Atopic Dermatitis, its Systemic Nature and its Therapeutic Implications
Atopic dermatitis (AD) is the most common and…
reachmd.com
secure.jbs.elsevierhealth.com
secure.jbs.elsevierhealth.com
secure.jbs.elsevierhealth.com
secure.jbs.elsevierhealth.com
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase…
onlinelibrary.wiley.com
Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
globenewswire.com
FDA Approves Dupilumab (Dupixent) for Eczema
Designated a breakthrough therapy, dupilumab spares…
medscape.com